A bipartisan group of congressional lawmakers filed a bill this week to clarify that federal “Right to Try” (RTT) laws give seriously ill patients access to Schedule I drugs, including marijuana and psychedelics like psilocybin and MDMA.
While the bipartisan measure would make a technical amendment to the text of existing law, the primary purpose is to clarify—in the face of Drug Enforcement Administration (DEA) objections—that RTT policy, as signed into law by then-President Donald Trump, already means that patients with terminal health conditions should be able to obtain and use investigational drugs that have undergone clinical trials, even if they’re Schedule I controlled substances.
Share this post
